SLC5A2 and type 2 diabetes mellitus: EMPA-REG OUTCOME, which investigated the effects of the sodium-glucose transporter 2 (SGLT2) inhibitor empagliflozin on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk, demonstrated a substantial reduction in CVD death and heart failure hospitalisations with empagliflozin but no effect on non-fatal CVD events [42].